Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Royal Marsden NHS Foundation Trust, Kyoto University, Texas Oncology, Baylor University Medical Center, NSABP Foundation, University of Pittsburgh, Institut de Cancérologie de l'Ouest, Universitair Ziekenhuis Leuven, National Taiwan University Hospital, University of St. Gallen, Trakya University, Dana-Farber Cancer Institute, Mayo Clinic in Arizona, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Gdańsk Medical University, D’Or Institute for Research and Education, Ospedale Policlinico San Martino, University of Genoa, National Center for Global Health and Medicine, Eli Lilly (United States), Loxo Oncology at Lilly (United States), Ludwig-Maximilians-Universität München, Hospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Cáncer, GEICAM – Spanish Breast Cancer Group